Evidence map›Paper›PMID 42513179›Full record

ReviewMolecules (Basel, Switzerland)2026

Nanoparticle Engineering in Modern Vaccinology: From Delivery Platforms to Immune-Programming Architectures.

Andrey Bogoyavlenskiy, Vladimir Berezin, Madina Alexyuk, Pavel Alexyuk, Elmira Omirtayeva

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Andrey BogoyavlenskiyResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Vladimir BerezinResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.ORCID 0000-0003-2648-8975
Madina AlexyukResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.
Pavel AlexyukResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.ORCID 0000-0003-3638-3341
Elmira OmirtayevaResearch and Production Center for Microbiology and Virology, Almaty 050010, Kazakhstan.

Funding

Ministry of Science and Higher Education of the Republic of Kazakhstan AP23488557
6 · The paper itself

Abstract

Recent advances in vaccinology have accelerated the shift from conventional live-attenuated and inactivated vaccines toward subunit and nucleic acid-based platforms. Although these next-generation vaccines offer improved safety, rapid adaptability, and manufacturing flexibility, their relatively low intrinsic immunogenicity often requires efficient adjuvants and delivery systems. Nanoparticle-based vaccine platforms have therefore emerged as versatile tools capable of protecting antigens, improving targeted delivery, and modulating both innate and adaptive immune responses. This review summarizes the major classes of nanovaccine platforms, including lipid and polymeric nanoparticles, self-assembling protein nanostructures such as virus-like particles and ferritin nanocages, saponin-based self-assembling complexes, and inorganic nanomaterials. Particular attention is given to how vaccine performance is determined not only by material composition but also by nanoparticle physicochemical properties, biodistribution, cellular uptake, and mechanisms of immune activation. We further discuss the major challenges limiting clinical translation, including scalable manufacturing, safety evaluation, quality control, regulatory requirements, and long-term biocompatibility. Finally, emerging strategies involving hybrid and personalized nanovaccine platforms are highlighted, illustrating how nanotechnology and immunoengineering are transforming vaccine development for both prophylactic and therapeutic applications.

Indexed as

NanoparticlesVaccinologyAdjuvants, ImmunologicAdjuvants, VaccineAnimalsDrug Delivery SystemsHumansNanotechnologyNanovaccinesVaccine DevelopmentAdjuvants, ImmunologicAdjuvants, VaccineNanovaccinesadjuvantsantigen displayimmunoengineeringISCOMslipid nanoparticlesnanovaccinesvirus-like particles (VLPs)

Identifiers

PMID42513179
PMCPMC13414965

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.